April 20, 2026 INVESTOR DEADLINE FRIDAY: Navan, Inc. (NAVN) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action
April 20, 2026 Immunofoco Presents Preclinical Data for IMV102, an In Vivo CAR-T Candidate, Demonstrating Durable Tumor Control at the AACR 2026
